Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Articles published by Merck & Co., Inc.

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

18 19 Next >

Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics

September 05, 2023

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference

September 05, 2023

From Merck & Co., Inc.

Via Business Wire

European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

August 29, 2023

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Citi 18th Annual BioPharma Conference

August 29, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616

August 25, 2023

From Merck & Co., Inc.

Via Business Wire

Merck and Eisai Provide Update on Phase 3 LEAP-010 Trial Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Patients With Certain Types of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

August 25, 2023

From Merck & Co., Inc.

Via Business Wire

LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone Approved in Japan for the Treatment of BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

August 24, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Announces WELIREG® (belzutifan) Phase 3 LITESPARK-005 Trial Met Primary Endpoint of Progression-Free Survival in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma

August 18, 2023

From Merck & Co., Inc.

Via Business Wire

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

August 03, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Announces Second-Quarter 2023 Financial Results

August 01, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Announces Phase 3 KEYNOTE-756 Trial Met Primary Endpoint of Pathological Complete Response (pCR) Rate in Patients With High-Risk, Early-Stage ER+/HER2- Breast Cancer

July 28, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Announces V116, an Investigational, 21-valent Pneumococcal Conjugate Vaccine Specifically Designed for Adults, Met Key Immunogenicity and Safety Endpoints in Two Phase 3 Trials

July 27, 2023

From Merck & Co., Inc.

Via Business Wire

Merck and Moderna Initiate Phase 3 Study Evaluating V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) for Adjuvant Treatment of Patients with Resected High-Risk (Stage IIB-IV) Melanoma

July 26, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Announces Fourth-Quarter 2023 Dividend

July 25, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive European Union CHMP Opinion for Gefapixant

July 21, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)

July 21, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Announces Phase 3 KEYNOTE-A18 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer

July 19, 2023

From Merck & Co., Inc.

Via Business Wire

Merck to Hold Second-Quarter 2023 Sales and Earnings Conference Call on Aug. 1

June 29, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Provides Update on Phase 3 KEYNOTE-585 Trial in Locally Advanced Resectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

June 20, 2023

From Merck & Co., Inc.

Via Business Wire

Merck Completes Acquisition of Prometheus Biosciences, Inc.

June 16, 2023

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Met Primary Endpoint of Progression-Free Survival as First-Line Treatment in Patients With HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

June 16, 2023

From Merck & Co., Inc.

Via Business Wire

U.S. District Court for the District of New Jersey Rules in Favor of Merck in Patent Infringement Lawsuit Related to BRIDION® (sugammadex)

June 13, 2023

From Merck & Co., Inc.

Via Business Wire

Merck to Present Data for Efinopegdutide (MK-6024), an Investigational GLP-1/Glucagon Receptor Co-agonist, in Patients with Nonalcoholic Fatty Liver Disease (NAFLD) at EASL 2023

June 12, 2023

From Merck & Co., Inc.

Via Business Wire

FDA Accepts Application for Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Advanced or Unresectable Biliary Tract Cancer

June 08, 2023

From Merck & Co., Inc.

Via Business Wire

U.S. FDA Approves New Indication for Merck’s PREVYMIS® (letermovir) for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Adult Kidney Transplant Recipients

June 06, 2023

From Merck & Co., Inc.

Via Business Wire

Merck to Participate in the Goldman Sachs 44th Annual Global Healthcare Conference

June 06, 2023

From Merck & Co., Inc.

Via Business Wire

Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery Reduced the Risk of Event-Free Survival Events by 42% Versus Pre-Operative Chemotherapy in Resectable Stage II, IIIA or IIIB NSCLC

June 03, 2023

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Unresectable Advanced Pleural Mesothelioma

June 03, 2023

From Merck & Co., Inc.

Via Business Wire

FDA Approves LYNPARZA® (olaparib) Plus Abiraterone and Prednisone or Prednisolone for Treatment of Adult Patients With BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

June 01, 2023

From Merck & Co., Inc.

Via Business Wire

KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Demonstrates Long-Term, Durable Survival Benefit Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma

May 25, 2023

From Merck & Co., Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 15

...

18 19 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Articles published by Merck & Co., Inc.

Starting at /week.